Microcap Ledger Vistagen Therapeutics, Inc. $VTGN
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- South San Francisco, CA
- Fiscal year end
- March 31
- Shares outstanding
- 44,376,911 [10-Q 2026-08-14]
What the company doesAI summary of filing
Vistagen Therapeutics is a late clinical-stage biopharmaceutical company developing intranasal pherine product candidates for neuropsychiatric and other conditions. The company's pipeline includes five clinical-stage candidates: fasedienol for social anxiety disorder (currently in Phase 3), itruvone for major depressive disorder, refisolone for menopausal hot flashes, PH15 for psychomotor impairment due to mental fatigue, and PH284 for cancer cachexia. The company also has AV-101, an oral prodrug candidate for NMDAR-related neurological disorders. Vistagen is pre-revenue and generates income through upfront and milestone payments from licensing agreements, including a $5 million upfront payment from AffaMed and a $1.5 million payment from Fuji Pharma for exclusive negotiation rights. [10-K 2026-06-15]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 3 months to Jun 2026 | $1.48M | −$13.03M | −$14.71M | $16.99M | [10-Q 2026-08-14] |
| FY ended Mar 2026 | $1.27M | −$69.69M | −$66.44M | $30.79M | [10-K 2026-06-15] |
| FY ended Mar 2025 | $486.0K | −$51.42M | −$42.10M | $67.13M | [10-K 2026-06-15] |
- Quarterly cash burn
- −$14.71M
- Cash runway Estimate
- ~3.5 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-06 | 27,843,466 | [10-Q 2024-11-07] |
| 2025-02-11 | 28,862,085 | [10-Q 2025-02-13] |
| 2025-06-10 | 29,157,733 | [10-K 2025-06-17] |
| 2025-08-04 | 30,680,471 | [10-Q 2025-08-07] |
| 2025-11-12 | 39,495,451 | [10-Q 2025-11-13] |
| 2026-02-11 | 39,620,317 | [10-Q 2026-02-12] |
| 2026-06-12 | 41,032,453 | [10-K 2026-06-15] |
| 2026-08-10 | 44,376,911 | [10-Q 2026-08-14] |
- Shelf registration
- S-3 filed 2024-02-13; declared effective 2024-02-29 [S-3 2024-02-13]
Listing status
Current status: 3 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-08-05. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-08-05 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-08-05] |
| 2026-04-02 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-04-02] |
| 2026-02-06 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-02-06] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-06-30 | Adler Reid G. | grant | 36,818 | $0.19 | [4 2026-07-02] |
| 2026-06-30 | Tressler Nick B. | grant | 11,712 | $0.19 | [4 2026-07-02] |
| 2026-06-30 | Singh Shawn | grant | 36,818 | $0.19 | [4 2026-07-02] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-09 | 8-K | Director or officer change |
| 2026-09-25 | 8-K | Regulation FD disclosure |
| 2026-09-24 | 8-K | Other events |
| 2026-09-22 | 8-K | Other events |
| 2026-09-11 | 8-K | Shareholder vote results |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 10-Q | Quarterly report |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 8-K | Results of operations |
| 2026-08-06 | 8-K | Regulation FD disclosure; Other events |
| 2026-08-05 | 8-K | Listing notice or transfer |
Alerts for $VTGN
Email me when Vistagen Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.